| 11.03 -1.12 (-9.22%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 15.27 | 1-year : | 17.71 |
| Resists | First : | 13.07 | Second : | 15.17 |
| Pivot price | 11.11  |
|||
| Supports | First : | 9.68 | Second : | 8.06 |
| MAs | MA(5) : | 11.27 |
MA(20) : | 11.69 |
| MA(100) : | 10.27 |
MA(250) : | 8.61 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 40.4 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 17.95 | Low : | 5.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARCT ] has closed above bottom band by 47.2%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.19 - 12.25 | 12.25 - 12.29 |
| Low: | 10.45 - 10.52 | 10.52 - 10.57 |
| Close: | 10.92 - 11.04 | 11.04 - 11.11 |
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Sat, 31 Oct 2026
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3 - TradingView
Mon, 21 Sep 2026
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program (NASDAQ:ARCT) - Seeking Alpha
Thu, 27 Aug 2026
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Thu, 06 Aug 2026
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 7.9 (%) |
| Held by Institutions | 77.1 (%) |
| Shares Short | 5,380 (K) |
| Shares Short P.Month | 6,100 (K) |
| EPS | -3.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | 0 % |
| Operating Margin | -863.3 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -46.4 % |
| Qtrly Rev. Growth | -89.5 % |
| Gross Profit (p.s.) | -2.03 |
| Sales Per Share | 1.03 |
| EBITDA (p.s.) | -3.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | -3.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 10.67 |
| Price to Cash Flow | -4.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|